Nesp

Nesp Adverse Reactions

darbepoetin alfa

Manufacturer:

Dexa Medica
Full Prescribing Info
Adverse Reactions
Adverse reactions were reported in 472 (32.3%) of 1,462 patients treated with NESP. The major adverse reactions were increased blood pressure in 248 cases (17.0%), shunt thrombosis/occlusion in 44 cases (3.0%), headache in 29 cases (2.0%) and malaise in 20 cases (1.4%).
Clinically significant adverse reaction: Cerebral infarction: Since cerebral infarction may occur, patients should be closely monitored. If any abnormalities are observed, appropriate measures such as discontinuation of NESP should be taken.
Cerebral hemorrhage: Since cerebral hemorrhage may occur, patients should be closely monitored. If any abnormalities are observed, appropriate measures such as discontinuation of NESP should be taken.
Hepatic function disorder, jaundice: Since hepatic function disorder and/or jaundice accompanied by increased ALT (GPT), γ-GPT, etc. may occur, patients should be closely monitored. If any adnormalities are observed, appropriate measures such as discontinuation of NESP should be taken.
Hypertensive encephalopathy: Since hypertensive encephalopathy may occur, patients should be closely monitored for changes in the blood pressure, etc. during the treatment.
Shock and anaphylactoid reactions: Since shock and/or anaphylactoid reactions (urticaria, dyspnea, lip edema, pharyngeal edema, etc.) may occur, patients should be closely monitored. If any abnormalities are observed, NESP should be discontinued and appropriate measures should be taken.
Pure red cell aplasia: Pure red cell aplasia accompanied by production of anti-erythropoietin antibodies may occur. If such a problem is observed, NESP should be discontinued and appropriate measures should be taken.
Myocardial infarction, pulmonary infarction: Since myocardial infarction and/or pulmonary infarction may occur, patients should be closely monitored. If any abnormalities are observed, appropriate measures such as discontinuation of NESP should be taken.
Other adverse reactions: Incidence of adverse reactions is listed by frequency. Frequencies are defined as: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000), not known (cannot be estimated). (See Table 4.)


Click on icon to see table/diagram/image

Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in